Post-ESMO update & “What now for CDK4/6 inhibitors?” 
8th November 2022 | 18:30 – 20:00 GMT

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Ltd.

UK | November 2022 | 248254

​

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.

​

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com